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1. Introduction
Renal  cell  carcinoma  is  often  associated  with  paraneoplastic  syndromes  caused  by  the
secretion  of  tumor  cell  products  such  as  hormones,  cytokines,  growth  factors  and  tu‐
mor  antigens,  which  show  manifestations  including  impaired  glucose  metabolism,  hy‐
percalcemia,  hypertension,  Cushing  syndrome,  polycythemia,  thrombosis,  eosinophilia,
leukemoid  reactions  and  amyloidosis  [1].  It  has  been  reported  that  10-40%  of  patients
with  renal  cell  carcinoma  present  paraneoplastic  symptoms  [1].  However,  paraneoplas‐
tic  glomerulonephritis  associated  with  renal  cell  carcinoma  has  often  been  overlooked,
for  the  urinary  abnormalities  including proteinuria  and hematuria  are  often  interpreted
as  clinical  manifestations  of  the  tumor  itself,  especially  when  the  proteinuria  is  non-
nephrotic.
The  term of  paraneoplastic  glomerulopathy was  first  described by Galloway in  1922  in
a  case  of  nephrotic  syndrome  associated  with  Hodgkin’s  disease  [2].  Hodgkin’s  lym‐
phoma  is  associated  with  minimal  change  nephrotic  syndrome,  while  solid  carcinomas
including  lung  cancer  and  carcinomas  of  the  gastrointestinal  tract  frequently  develop
membranous  nephropathy,  which  is  the  most  common  paraneoplastic  glomerulopathy
[3,4].  Although renal  cell  carcinoma is  not  a  frequent  cause of  paraneoplastic  glomerul‐
opathy,  recent  advances  in  the  study of  the  molecular  mechanism of  renal  cell  carcino‐
ma  as  a  cytokine  producing  tumor  have  promoted  a  better  understanding  of  the
mechanism  of  paraneoplastic  nephropathy  associated  with  renal  cell  carcinoma.  In  this
chapter,  I  will  discuss  the  mechanisms  of  paraneoplastic  nephropathies  associated  with
renal  cell  carcinoma.
© 2013 Tojo; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Pathological types of renal cell carcinoma and molecular mechanisms of
paraneoplastic syndrome
Renal cell carcinoma accounts for 85 % of renal neoplasms, and 25% of patients with renal
cell carcinoma show advanced disease with local invasion or metastasis at the time of diag‐
nosis [5]. Renal cell carcinoma is classified pathologically into five types: clear cell (75%),
papillary (12%), chromophobe (4%), oncocytoma (4%), collecting duct carcinoma (<1%), and
unclassified (3-5%) [5]. The most common type, clear cell renal cell carcinoma, shows hyper‐
vascularity. About 60% of sporadic clear cell renal cell carcinoma have mutations in the von
Hippel-Lindau tumor suppressor gene (VHL) [6], which is a causative gene for von Hippel-
Lindau disease, an autosomal dominant familial cancer syndrome consisting retinal angio‐
ma, hemangioblastoma of the central nervous system, pheochromocytomas, and clear cell
renal cell carcinoma. VHL protein normally suppresses hypoxia-inducible genes by inhibit‐
ing HIF-1α [7] (Figure 1). However, when VHL protein is lost in clear cell renal cell carcino‐
ma, various cytokines and growth factors induced by HIF-1α are enhanced; vascular
endothelial growth factor (VEGF) which stimulates angiogenesis of carcinoma, platelet-de‐
rived growth factor (PDGF) and transforming growth factor alpha (TGF- α), which lead to
tumor growth, glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX), which
leads to tumor cell survival in an acidic environment [8-10]. NF-kB activity is also regulated
by VHL protein, and cytokine-inducible transcription factors including NF-kB and STAT3
are activated in renal cell carcinoma [11-15]. Renal cell carcinoma tissue and cell lines of the
tumor express mRNA of IL-6 and IL-6 receptor [16, 17], which may play a role in cancer cell
growth in an autocrine or paracrine manner.
Figure 1. Molecular mechanisms of renal cell carcinoma as a cytokine-producing tumor.
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The von Hippel-Lindau protein (pVHL) binds with hypoxia inducible factor 1α (HIF-1α)
transcription factor and promotes the ubiqutination of HIF-1α, resulting in degradation by
the proteasome under normoxic conditions. In renal cell carcinoma, the absence of wild type
pVHL stimulates the accumulation of HIF-1α and activates transcription at hypoxia-re‐
sponse elements (HREs) in genes including vascular endothelial growth factor (VEGF), pla‐
telet-derived growth factor (PDGF), transforming growth factor α (TGF-α) and TGF-β,
glucose transporter (GLUT-1) and carbonic anhydrase IX (CA IX).
MMP: matrix metalloproteinase; Ang-2: angiopoietin-2; Aglike-4: angiopoietin-like 4;
COX-2: cyclooxygenase-2; BNIP3: BCL2/adenovirus E1B 19 kD interacting protein 3; PAX2:
paired box gene 2.
The serum levels of VEGF and IL-6 are increased according to the stage of renal cell carcino‐
ma, whereas TNF-α and IL-1β showed a slight increase as they are probably produced by
infiltrating monocytes or macrophages (Figure 2) [18,19]. This indicates that clear cell renal
cell carcinoma is a cytokine-producing tumor, whose functions are linked to the develop‐
ment of the various features of the paraneoplastic syndrome [9,20].
Figure 2. Serum vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α) and
interleukin-1β (IL-1β) in various stages of renal cell carcinoma. Adapted from [18] and [19].
2. Incidence of paraneoplastic syndrome and glomerulopathy in renal
cell carcinoma
The most frequent features of the paraneoplastic syndrome in renal cell carcinoma are hy‐
percalcemia, hypertension and polycythemia. Their prevalence and their causative hor‐
mones and cytokines are listed in Table1 [1].
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Phenomenon Prevalence % Hormones and cytokines
Hypercalcemia 13-20% Non-bone metastatic disease 50%, PTH, PTHrP, TGF-α, β,
OAF, IL-1, TNF
Hypertension 40% Renin
Polycythemia 1-8% Erythropoietin
Nonmetastatic hepatic dysfunction
(Stauffer’s syndrome)
3-20% Hepatotoxines, lysosomal enzymes stimulating hepatic
cathepsins or phosphatases, IL-6
Constitutional syndrome (fever, weight
loss, fatigue)
20-30% TNF-α, IL-6. IL-1, prostaglandins
6% β-HCG
Cushing’s syndrome 2% ACTH
Abnormal glucose metabolism Insulin, glucagon
Galactorrhea Prolactin
Amyloidosis 3-8% SAA protein
Neuromyopathies rare unknown
Nephropathy
Vasculopathy
Coagulopathy
PTHrP: parathyroid hormone-related peptide, OAF: osteoclast activating factor, TNF: tumor necrosis factor, HCG: hu‐
man chorionic gonadotropin, ACTH: adrenocorticotropin, SAA: serum amyloid A.
Table 1. Prevalence and features of paraneoplastic syndromes in renal cell carcinoma.
Paraneoplastic glomerulopathy is believed to be a rare manifestation of the paraneoplastic
syndrome. However, immunohistochemical analysis of resected kidneys from 60 patients of
renal cell carcinoma revealed 27% of them had immune complex nephropathy including 11
patients (18%) with IgA nephropathy and 5 patients (8%) with focal segmental glomerulo‐
sclerosis [21]. Another immunofluorescence study revealed a positive staining for C3, IgM,
or IgA in the mesangial deposits in 35% (14/40) of patients with renal cell carcinoma versus
5.4% in the control subjects [22] (Table 2). Thus, the occurrence of glomerular diseases is not
so rare in renal cell carcinoma.
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Prevalence % Outcomes after resection of renal
carcinoma
Reference
IgA nephropathy 11/60 (18%) Remission 6, Azotemia 2 Magyarlaki [21]
FSGS 5/60 (8%) Azotemia 3
Diabetic nephropathy 3/60 (5%) Nephrotic /Azotemia 2
Nephrosclerosis 4/60 (7%) Nephrotic /Azotemia 2
Tubulointerstitial nephritis 16/60 (27) -
IgA/C3 deposition 1/40 (2.5%) N.D. Beaufils [22]
C3/IgM deposition 13/40 (33%)
CEA deposition 2/9 (22%)
HBs Ag/Ab deposition 6/29(21%)
Table 2. Evaluation of glomerulopathy in resected kidneys of renal cell carcinoma patients.
3. Diagnosis and mechanism of paraneoplastic glomerulopathy
associated with renal cell carcinoma
Recent development or worsening of diabetes mellitus, increased platelet or C-reactive pro‐
tein (CRP), and hypercalcemia also suggests the existence of paraneoplastic syndrome. Glo‐
merulonephritis is considered when urinalysis shows dysmorphic red blood cells and red
blood cell casts, as hematuria caused by renal cell carcinoma usually shows isomorphic red
blood cells. When proteinuria exceeds 1g per day, it is also better to speculate overlapping
glomerulonephritis and examine serological tests including immunoglobulins (IgG, IgA,
IgM), complements (CH50, C3, C4), anti-nuclear antibody, and anti-dsDNA antibody. A fi‐
nal diagnosis of glomerulonephritis can only be given by a renal biopsy. Renal cysts or
masses identified by renal ultrasonography at the time of renal biopsy should be further in‐
vestigated with CT and MRI. Renal cancer will progress rapidly after steroid therapy for
glomerulonephritis.
The diagnosis of paraneoplastic glomerulopathy will be suggested following the criteria; 1)
existence of a time relationship between the diagnosis of the glomerulopathy and cancer, 2)
no obvious etiology for glomerular diseases, 3) clinical or histological remission of glomerul‐
opathy after complete remission by surgical removal of carcinoma, 4) recurrence of the carci‐
noma associated with deterioration of glomerular diseases [3,23].
As mentioned above, inactivation of the VHL gene by frame-shift mutation is observed in
about 60% of sporadic RCC [5]. Activated HIF-1α without VHL protein stimulates hypoxia-
related proteins such as vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF), which lead to tumor growth and trigger angiogenesis (Figure 1)
[8,10]. The increased VEGF accelerates glomerular permeability and causes proteinuria, and
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PDGF and IL-6 stimulates mesangial cell proliferation, and TGF-β increases the mesangial
matrix, contributing to the development of glomerulonephritis.
It is interesting that IgA nephropathy showed a higher prevalence than membranous nephr‐
opathy in renal cell carcinoma, whereas about 50% of glomerulopathies associated with gas‐
trointestinal neoplasias and lung cancers were membranous nephropathy (Table 3). The
mechanisms of paraneoplastic nephropathy may be different in renal cell carcinoma com‐
pared with gastrointestinal neoplasias and lung cancers. The paraneoplastic nephropathy of
renal cell carcinoma may depend more upon overproduction of cytokines rather than cross-
reaction with tumor antigen and production of autoantibodies.
Renal cell
carcinoma
N=49
Gastrointestinal neoplasia
N=48
Lung cancer
N=41
Membranous nephropathy 10 (20%) 26 (54%) 20 (49%)
IgA nephropathy 15 (31%) 1 (2%) 2 (5%)
Minimal change disease 6 (12%) 9 (19%) 9 (22%)
Focal segmental glomerulonephritis 5 (10%) 2 (4%) 1 (2%)
Membranoproliferative
glomerulonephritis
3 (6%) 2 (4%) 5 (12%)
Crescentic glomerulonephritis 10 (20%) 8 (17%) 4 (10%)
Table 3. Type of glomerulopathy in renal cell carcinoma compared with gastrointestinal neoplasia and lung cancer.
Modified from [3].
4. Types of paraneoplastic nephropathy
4.1. IgA nephropathy and renal cell carcinoma
Although IgA nephropathy is more common in younger patients, when it occurs in patients
older than 60 years, a high prevalence of malignancy (23%) is observed [24]. Solid tumors
that invade mucosal tissue like the respiratory tract, the buccal cavity, and the nasopharynx
increase circulating IgA levels and show deposition of IgA in the mesangium [24]. Several
cases of IgA nephropathy associated with renal cell carcinoma have been reported previous‐
ly [21,25-28]. In Figure 3, a 66 year-old male diagnosed IgA nephropathy with mesangial
IgA deposition but weak C3 staining showed a rapid increase in renal cyst during steroid
treatment, and a clear cell renal cell carcinoma was found in the resected kidney (Figure 3).
The infiltrating plasma cells around the renal cell carcinoma produced IL-6 and IgA (Figure
3). Elevated levels of IL-6 have been reported in 18 (25%) of 71 patients with renal cell carci‐
noma [29], and IL-6 increased in more than 50% of patients with metastatic renal cell carci‐
noma, playing a role as a prognostic marker [19,20,30,31]. IL-6 stimulates IgA production
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[32], thus, the elevated IL-6 in renal cell carcinoma may increase circulating IgA, which de‐
posits in the mesangial area causing IgA nephropathy.
Figure 3. Clear cell renal cell carcinoma in association with IgA nephropathy. (A) PAS staining of clear cell carcinoma
with a capsule. (B) immunostaining for IL-6 showing positive immunoreactivity in the infiltrating lymphocytes and
plasma cells around the clear cell carcinoma and capsule. (C) IgA immunoreactivity positive in the plasma cells around
renal cell carcinoma. (D) Renal biopsy sample showing segmental mesangial cell proliferation. (E) Immunofluores‐
cence showed positive staining of IgA in the mesangial area, and weak staining of C3 (F).
4.2. Membranous nephropathy and renal cell carcinoma
The most frequent paraneoplastic glomerulopathy associated with solid tumors is membra‐
nous nephropathy and it is easy to detect because most of the cases manifest the nephrotic
syndrome (paraneoplastic nephrotic syndrome) [3,23,33]. Since membranous nephropathy
associated with malignancy has been attributed to tumor antigen-antibody immune com‐
plex formation, the cancer related antigens have been identified in immune complex in some
cases including PSA in prostate cancer, CEA in gastrointestinal cancer [34]. Renal cell carci‐
noma has been reported to be associated with membranous nephropathy [35-43], but its
prevalence is lower compared with gastrointestinal cancer and lung cancer (Table 3). As an‐
tibodies against phospholipase A2 receptor antibody have been identified in 70 % of pa‐
tients with primary membranous nephropathy [44], a diagnosis of secondary membranous
nephropathy should be considered when it is negative. IgG subclass immunofluorescence is
useful to distinguish the primary membranous nephropathy in which IgG4 is stained pre‐
dominately. In a case of secondary membranous nephropathy associated with renal cell car‐
cinoma, showed predominantly IgG1 and IgG3 staining compared to IgG4 (Figure 4). The
renal tubular epithelial antigen (RTE) has been identified in one case of renal cell carcinoma
[45], but in most cases the tumor antigen-antibody complex were not identified in the serum
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and elutes of glomeruli in patients with membranous nephropathy associated with renal cell
carcinoma [35,40].
Even though tumor antigen-antibodies have not been identified yet, renal tumors may have
some contribution to the pathogenesis of membranous nephropathy because nephrotic syn‐
drome is transiently ameliorated after tumor excision [40-43].
Figure 4. Secondary membranous nephropathy associated with clear cell renal cell carcinoma.
Light microscopy of PAM staining demonstrated thickening of the glomerular basement
membrane, and electron microscopy revealed subepithelial electron dense deposits with
spike formation. IgG1 and IgG3 were more strongly stained along the capillary wall than
IgG4, suggesting secondary membranous nephropathy.
4.3. Minimal change disease and focal segmental glomerulosclerosis with renal cell
carcinoma
In contrast to Hodgkin’s disease, renal cell carcinoma associated with minimal change neph‐
rotic syndrome is rare [46,47]. The onset of nephrotic syndrome is simultaneous [48,49] or
precedes the diagnosis of renal tumor by 3-4 weeks [47,50], and there was a case in which
complete remission was achieved after nephrectomy without steroids [49]. These lines of
evidence suggest that occurrence of minimal change nephrotic syndrome may be a paraneo‐
plastic syndrome associated with renal cell carcinoma. Renal oncocytoma, characterized by
increased cytoplasmic volume containing abundant fine eosinophilic granules and mito‐
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chondria, also show the paraneoplastic minimal change nephrotic syndrome [51]. The
pathogenesis of minimal change nephrotic syndrome in not clear, but T cell-mediated im‐
mune response has been postulated. The increased secretion of VEGF from renal cell carci‐
noma may alter glomerular permeability and induce minimal change nephrotic syndrome.
Magyarlaki et al [21] reported 5 cases (8%) of focal segmental glomerulosclerosis in 60 au‐
topsy cases of renal cell carcinoma, however, there are only a few reports of focal segmental
glomerulosclerosis with renal cell carcinoma [52] and Wilms’ tumor [53]. Glomerulosclerotic
lesions are often observed in the renal parenchyma adjacent to a tumor, so parenchymal
compression and urinary outflow obstruction by renal tumor may be involved in the devel‐
opment of focal segmental glomerulosclerosis.
4.4. Crescentic rapidly progressive glomerulonephritis and vasculitis with renal cell
carcinoma
Crescentic glomerulonephritis with rapid progressive renal failure in conjunction with renal
cell carcinoma has been reported previously [54-57]. The prevalence of renal cell carcinoma
is significantly higher in patients with ANCA-positive Wegener’s granulomatosis (7 in 477
patients) than in those with rheumatoid arthritis (1 in 479 patients) with an odds-ratio for
development of renal cell carcinoma of 8.73 (p=0.0464, 95% CI 1.04-73.69) [58]. In most of the
7 cases, Wegener’s granulomatosis was developed shortly after or simultaneously with the
diagnosis of renal cell carcinoma [58]. There are many infiltrating cells around the clear cell
renal cell carcinoma (Figure 5), and the chronic inflammation observed in renal cell carcino‐
ma may induce anti-neutrophil cytoplasmic antibodies (ANCA) or the renal cancer cells
may serve as an antigen source [59]. The renal prognosis in crescentic glomerulonephritis
with renal cell carcinoma becomes poor when an anti-GBM antibody exists, and a rapid pro‐
gression to end-stage renal failure with need of hemodialysis has been reported [54].
Figure 5. ANCA-related crescentic nephritis associated with renal cell carcinoma. A) The clear cell renal cell carcinoma
was surrounded by many infiltrating inflammatory cells including lymphocytes, plasma cells and some neutrophils. B)
Some glomeruli around the renal cell carcinoma demonstrated crescents, and the MPO-ANCA level was decreased
from 217 EU to 99 EU after nephrectomy.
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Membranoproliferative glomerulonephritis with crescents has been reported in patients
with renal cell carcinoma, and elective nephrectomy improved both proteinuria and renal
function after seven months [60]. Henoch-Schönlein purpura with leukocytoclastic vasculitis
was also observed in a 25-year-old man with a small size (0.9x0.8cm) clear cell renal cell car‐
cinoma [61]. Vasculitis associated with cancer is common in lymphoma and leukemia, but
only 37 cases associated with solid tumor malignancies have been reported [62], including
lung cancer, prostate cancer, colon cancer, renal cell carcinoma, breast cancer and squamous
cell carcinoma [63]. Cytokine production by malignant cells, like renal cell carcinoma, may
contribute to the development of vasculitis.
4.5. Scleroderma and lupus erythematosus with renal cell carcinoma
Renal cell carcinoma has an immunogenic feature. An interesting case was reported recently
where clinical manifestations of scleroderma and proteinuria associated with renal cell carci‐
noma and membranous nephropathy in a 55-year-old man improved after heminephrecto‐
my of the renal cell carcinoma [43]. Similarly, lupus nephritis developed in a 64 year-old
male with clear cell renal carcinoma with para-aortic lymph node metastasis. After one year
of partial nephrectomy, the renal cell carcinoma recurred with nephrotic syndrome and per‐
icarditis, and laboratory examination showed an increase in IgG (3449 mg/dL), IgA (371 mg/
dL), IgM (715 mg/dL), anti-nuclear antibody (x320) and anti-double strand DNA antibody
(41 IU/mL) with low complement levels (CH50 10 U/mL, C3 60, C4 10 mg/dL). Immunohis‐
tochemical examination of the resected kidney and para-aortic lymph nodes revealed in‐
creased infiltration of plasma cells producing IgG, IgM and IgA around the tumor (Figure
6), suggesting that renal cell carcinoma may have some role in the development of lupus er‐
ythematosus.
Figure 6. Immunohistochemistry for IgG, IgM, and IgA in the resected kidney of renal cell carcinoma and its para-aort‐
ic lymph node metastasis. The patient developed lupus erythematosus and nephrotic syndrome when renal cell carci‐
noma recurred and progressed.
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4.6. Amyloidosis associated with renal cell carcinoma
About 3% of patients with renal cell carcinoma develop systemic amyloidosis [64], and the
amyloid is composed of AA protein [65,66]. The renal cell carcinoma may be involved in the
stimulation of hepatic production of acute phase reaction proteins including serum amyloid
A protein, and the modification of amyloidogenic proteins by the monocyte-macrophage
system in the chronic inflammatory lesion of renal cell carcinoma, causing the secondary
amyloidosis. Remission of amyloidosis and nephrotic syndrome has been reported after
nephrectomy [65,67,68].
4.7. Tubulointerstitial nephritis
Tubulointerstitial nephritis is often difficult to identify because it does not show obvious ab‐
normalities in urine. However, 27% of patients with renal cell carcinoma showed tubuloin‐
terstitial nephritis in resected kidney (Table 2) [21]. Recently, as a mechanism of
tubulointerstitial nephritis, the antibody against carbonic anhydrase II (CAII) was identified
in Sjögren syndrome with renal tubular acidosis [69] and IgG4 related tubulointerstitial
nephritis [70]. Carbonic anhydrase is a zinc metalloenzyme that catalyzes the hydration of
carbon dioxide and the dehydration of bicarbonate in the proximal tubules and the distal
nephron including the intercalated cells of the collecting duct. CA has 15 isoforms and CAII
accounts for more than 95 % of CA activity in the kidney and exists in the cytosol, and the
remaining 5% renal CA is membrane associated CAIV and CAXII [71]. CAIX is not ex‐
pressed in the normal kidney, however, in renal cell carcinoma CAIX is induced by hypoxia
as a tumor-associated antigen [72,73]. Inactivation of the VHL gene complex leads to the sta‐
bilization of hypoxia inducible factor-1α which activates CAIX gene expression [74]. CAIX
may promote tumor growth and survival in hypoxic and acidic environments [73]. Serum
levels of CAIX are higher in clear cell renal cell carcinoma than non-clear cell renal cell carci‐
noma and it is a useful marker for the differential diagnosis of renal cell carcinoma and also
as a maker of tumor size [75]. It could be possible that an autoantibody against CAIX could
be induced and cause tubulointerstitial nephritis in renal cell carcinoma.
5. Treatment of paraneoplastic glomerulopathy associated with renal cell
carcinoma
The primary treatment for renal cell carcinoma is surgical excision including radical neph‐
rectomy, nephron-sparing partial nephrectomy, laparoscopic nephrectomy and percutane‐
ous ablation by radiofrequency heat or cryoablation [5]. Most cases of nephrotic syndrome
associated with renal cell carcinoma showed remission or transient reduction of proteinuria
just after nephrectomy as summarized in Table 4. It is interesting that only nephrectomy can
achieve remission of nephropathy with amyloidosis [65,67,68], which is usually refractory to
treatment. Some cases of IgA nephropathy, membranous nephropathy, crescentic glomeru‐
lonephritis and focal segmental nephrosclerosis associated with renal cell carcinoma pro‐
gressed to end stage renal failure. In addition to nephrectomy, treatment with prednisolone
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was attempted in some cases, especially in minimal change nephrotic syndrome, and
showed reduction of proteinuria. However, it is noteworthy to recognize that the cyst at the
time of biopsy rapidly enlarged after treatment with prednisolone for IgA nephropathy, and
a diagnosis of renal cell carcinoma was made later [28]. Thus, the first line of treatment of
paraneoplastic glomerulopathy associated with renal cell carcinoma is nephrectomy, and
the use of steroids should be limited only to cases of controlled renal cell carcinoma.
Glomerulopathy Age, sex Treatment Outcomes References
IgAN 61 M nephrectomy Remission Tanaka [26]
IgAN 8 cases nephrectomy Remission (6/8) Magyarlaki [21]
IgAN 58 M 66 M
59 M
Steroid, nephrectomy
Steroid 30mg,
nephrectomy
nephrectomy
Remission ESRD Remission Mimura [28]
MN 76 F nephrectomy Died (33 days) Stein [37]
MN 69 M steroid 50mg Died (6 months) Nishihara [38]
MN 62 M Partial nephrectomy PR Fujita [39]
MN 57 M nephrectomy TR/relapse Togawa [40]
MN 72M nephrectomy TR/ESRD Kapolas [41]
MN 77 F nephrectomy remission Kuroda [42]
MN 55 M nephrectomy remission Nunez [43]
MCNS 49 M Nephrectomy, steroid PR Forland [51]
MCNS 70 M nephrectomy Remission after biopsy Lee [49]
MCNS 69 M Steroid 80mg,
CPM150mg
Died of infection Abouchacra [48]
MCNS 64 F Nephrectomy, steroid
60mg
PR Woodrow [50]
MCNS 78 M nephrectomy, steroid
1mg/kg
Complete remission Auguet [47]
FSGS 48 M nephrectomy Worsened sCr Ejaz [52]
CresGN /GBM-Ab 74 M nephrectomy ESRD Hatakeyama [54]
CresGN/MPO-ANCA 68 F nephrectomy, steroid Remission Karim [56]
CresGN 35 F HD ESRD died on HD Jain [ 57]
MPGN 26 F nephrectomy remission Tydings [76]
MPGN 65 M nephrectomy remission Ahmed [60]
amyloidosis 66 F diuretics NS, Died (respiratory
failure)
Pras [66]
amyloidosis 58 F Nephrectomy,
splenectomy
Remission (7months) Vanatta [65]
amyloidosis 62 M nephrectomy Remission (3years) Karsenty [67]
amyloidosis 54 F nephrectomy Remission (5years) died of
relapse
Tang [68]
IgAN: IgA nephropathy, MN: membranous nephropathy, MCNS: minimal change nephrotic syndrome, FSGS: focal seg‐
mental glomerulosclerosis, cresGN: crescentic glomerulonephritis, MPGN: Membranoproliferative glomerulonephritis,
PR: partial remission, ESRD: end-stage renal disease, TR transient remission, CPM cyclophosphamide, HD: hemodialysis,
NS: nephrotic syndrome.
Table 4. Treatment and outcomes of glomerulopathy with renal cell carcinoma
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6. Molecular-target therapy related nephropathy in renal cell carcinoma
About  30%  patients  will  have  distant  metastasis  at  the  time  of  diagnosis,  and  medical
therapies including interleukin-2,  interferons,  and molecular-target  therapy are generally
offered  for  advanced  renal  cancer  as  listed  in  Table  5.  Interleukin-2  showed  transient
proteinuria  and  renal  dysfunction,  but  these  changes  are  reversible  and  did  not  cause
long-term intrinsic renal damage [77-79]. Interferons are well known to show proteinuria
in  15-20% of  patients  [80].  The  nephrotic  syndrome and acute  renal  failure  induced by
interferon therapy are histologically due to minimal change disease and acute tubuloin‐
terstitial nephritis [80-82].
Bevacizumab, a humanized monoclonal anti-vascular endothelial growth factor antibody,
is  used for  the treatment  of  metastatic  renal  cell  carcinoma,  but  adverse effects  such as
hypertension, anorexia and proteinuria are increased with combination therapy of bevaci‐
zumab  and  interferon  α  compared  with  interferon  α  monotherapy  [83,84].  High-dose
bevacizumab therapy showed proteinuria of more than 1+ in 64% of patients with renal
cell  carcinoma and nephrotic  range proteinuria  of  more than 3.5  g/day in 7.7% patients
[85].  Renal  biopsy  revealed  thrombotic  microangiopathy  in  two  patients  treated  with
Bevacizumab and interferon-α [86]. As VEGF is expressed in the podocyte and its recep‐
tors  are  found in glomerular  endothelial  cells,  blocking VEGF may disturb the function
of  VEGF  to  maintain  the  glomerular  capillary  permeability  barrier,  causing  thrombotic
microangiopathy [87,88].
Treatment of renal cell carcinoma with sunitinib or sorafenib, which inhibit the VEGF re‐
ceptor  and multi-tyrosine  kinases,  induced severe  nephrotic  syndrome with  acute  renal
failure,  and renal  biopsy revealed minimal change disease and thrombotic  microangiop‐
athy with acute tubular necrosis [89,90]. Sunitinib also develops other pathological forms
of renal diseases including acute interstitial nephritis [91], acute nephritic syndrome with
subendothelial  C3  deposition  [92],  FSGS [93],  and sorafenib  is  also  associated with  IgA
nephropathy  [94],  and  interstitial  nephritis  [95].  Withdrawal  of  sunitinib  or  sorafenib
with  or  without  use  of  steroids  ameliorated increased serum creatinine  and proteinuria
as well as hypertension and edema [91,93-95],  but in some advanced cases hemodialysis
was needed [89,  92]  or proteinuria persisted [90].  Thus,  early detection of renal  adverse
effects of these drugs is necessary.
Temsirolimus is a highly specific inhibitor of the mammalian target of rapamycin, which is a
central regulator of intracellular signaling pathways and an inhibitor of angiogenesis. Tem‐
sirolimus has prolonged overall survival in patients with advanced renal cell carcinoma
compared to interferon-α [96]. However, temsirolimus reduced synaptopodin and nephrin
expression in podocytes and induced nephrotic syndrome caused by focal segmental glo‐
merulosclerosis [97]. The amount of proteinuria decreased after withdrawal of temsirolimus,
so it is necessary to notice the nephrotic adverse effects of this drug.
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Medical therapy Mechanism Renal diseases References
Interleukin-2 immunomodulatory cytokine Proteinuria, transient
increase in sCr
Belldegrun [77]
Shalmi [78]
Guleria [79]
Interferon α, γ immunomodulatory cytokine proteinuria, MCNS, IN,
ARF
INF-α: Quesada [80]
IFN-γ: Nair [81], Tashiro [82]
Bevacizumab Humanized VEGF-neutralizing
antibody
Proteinuria, TMA Rini [83], Summers [84],
Roncone [86]
Sunitinib VEGF receptor and multiple
tyrosine kinase inhibitor
MCNS, iATN Chen [89]
AIN Winn [91]
AGN Rolleman [92]
FSGS, TMA Costero [93]
Sorafenib VEGF receptor and multiple
tyrosine kinase inhibitor
TMA, MCNS Overkleeft [90]
IgAN Jonkers [94]
AIN Izzedine [95]
Temsirolimus Inhibitor of the mammalian
target of rapamycin
FSGS Izzedine [97]
MCNS: minimal change nephrotic syndrome, IN: interstitial nephritis, ARF: acute renal failure, TMA: thrombotic micro‐
angiopathy, iATN: ischemic acute tubular necrosis, AGN:acute glomerulonephritis.
Table 5. Interleukin, interferon and molecular-target drugs related nephropathy in the renal cell carcinoma
7. Summary
Recent advances in the molecular understanding of renal cell carcinoma have shed light on
the mechanism of paraneoplastic glomerulopathy. Clear cell renal cell carcinoma with a
VHL gene mutation stimulates HIF-1α transcription, and produces various cytokines and
growth factors including VEGF, PDGF, TGF−α/β, IL-6, CAIX and EPO. Renal cell carcinoma
has a feature of cytokine disease or immunogenic disease, and enhanced cytokines and
growth factors stimulate lymphocytes and plasma cells, and the latter works as a causative
factor for various forms of paraneoplastic glomerulopathies. The precise mechanism of glo‐
merulonephritis has not been completely elucidated, and further investigation of renal cell
carcinoma related glomerulopathies will open a new perspective in the understanding of
glomerular diseases.
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